Insmed (NASDAQ:INSM) Given New $160.00 Price Target at Wells Fargo & Company

Insmed (NASDAQ:INSM) had its price objective trimmed by Wells Fargo & Company from $177.00 to $160.00 in a report released on Friday, MarketBeat Ratings reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on the stock. HC Wainwright boosted their price objective on shares of Insmed from $230.00 to $245.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Guggenheim reduced their target price on Insmed from $230.00 to $226.00 and set a “buy” rating on the stock in a report on Friday. Bank of America lifted their price target on Insmed from $211.00 to $213.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Barclays boosted their price target on Insmed from $231.00 to $237.00 and gave the stock an “overweight” rating in a report on Wednesday, April 1st. Finally, Morgan Stanley upgraded Insmed from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $166.00 to $212.00 in a research report on Monday, March 30th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $211.86.

Insmed Price Performance

INSM stock opened at $101.17 on Friday. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76. Insmed has a 12 month low of $64.85 and a 12 month high of $212.75. The firm has a market cap of $21.84 billion, a P/E ratio of -17.60 and a beta of 0.89. The company’s 50-day moving average price is $145.87 and its two-hundred day moving average price is $165.46.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. The company had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 121.03%. The firm’s quarterly revenue was up 229.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.42) EPS. On average, analysts anticipate that Insmed will post -2.41 earnings per share for the current fiscal year.

Insider Buying and Selling at Insmed

In related news, CEO William Lewis sold 10,699 shares of the company’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $143.97, for a total value of $1,540,335.03. Following the sale, the chief executive officer directly owned 301,185 shares in the company, valued at $43,361,604.45. This represents a 3.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Michael Alexander Smith sold 19,638 shares of the stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the sale, the insider directly owned 51,871 shares of the company’s stock, valued at $7,831,483.58. This represents a 27.46% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 174,589 shares of company stock worth $27,441,807. Insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On Insmed

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Insmed by 5.7% during the fourth quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock worth $3,668,127,000 after buying an additional 1,140,524 shares during the last quarter. Darwin Global Management Ltd. boosted its position in Insmed by 2.3% during the fourth quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company’s stock valued at $3,644,274,000 after acquiring an additional 475,832 shares during the last quarter. Capital International Investors boosted its position in Insmed by 1.0% during the third quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock valued at $1,087,830,000 after acquiring an additional 74,994 shares during the last quarter. State Street Corp grew its holdings in Insmed by 30.6% during the 4th quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock worth $905,312,000 after acquiring an additional 1,217,390 shares during the period. Finally, Artisan Partners Limited Partnership grew its holdings in Insmed by 49.0% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after acquiring an additional 1,623,342 shares during the period.

Trending Headlines about Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Insmed reported Q1 EPS of -$0.76, beating estimates, and revenue rose 229.7% year over year to $306 million. The company also reiterated major 2026 commercial goals, including at least $1 billion in BRINSUPRI revenue and $450 million to $470 million in ARIKAYCE revenue. Article: Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts at Royal Bank of Canada and Wells Fargo cut their price targets but kept bullish ratings, signaling they still see meaningful upside from current levels. RBC lowered its target to $205 from $220 and Wells Fargo cut to $160 from $177. Article: Benzinga report on RBC price target cut Article: The Fly report on Wells Fargo price target cut
• Neutral Sentiment: Insmed also highlighted progress on its pipeline and commercialization efforts, including positive ENCORE study results for ARIKAYCE and the start of the PALM-PAH study for TPIP. These updates support the long-term story, but they are less likely to move the stock immediately. Article: Insmed Q1 2026 Financial Results and Business Update
• Negative Sentiment: The stock is under pressure because Q1 sales came in below expectations and the company’s implied 2026 revenue guidance was below consensus, raising concerns that launch momentum may not be matching investor hopes. Article: Insmed’s Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
• Negative Sentiment: Higher first-quarter expenses also weighed on sentiment, with market commentary pointing to increased costs as another reason investors sold the shares after earnings. Article: Insmed Shares Tumble Amid Higher 1Q Expenses

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.